DelveInsight’s, “Dilated Cardiomyopathy – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Dilated Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Dilated Cardiomyopathy Understanding
Dilated Cardiomyopathy: Overview
Cardiomyopathies are disorders of the cardiac muscle that cause mechanical and/or electrical dysfunction that result in dilated, hypertrophic or restrictive pathophysiology. Dilated cardiomyopathy (DCM) is a non-ischaemic heart muscle disease with structural and functional myocardial abnormalities. The clinical picture of Dilated cardiomyopathy is defined by left or biventricular dilatation and systolic dysfunction in the absence of coronary artery disease, hypertension, valvular disease or congenital heart disease. The American Heart Association classifies Dilated cardiomyopathy as genetic, mixed or acquired, whereas the European Society of Cardiology (ESC) groups cardiomyopathy into familial (that is, genetic) or non-familial (that is, nongenetic) forms. The WHO defines Dilated cardiomyopathy as a serious cardiac disorder in which structural or functional abnormalities of the heart muscle can lead to substantial morbidity and mortality owing to complications such as heart failure and arrhythmia.
Symptoms
Many people with dilated cardiomyopathy have no symptoms or only minor symptoms, and live a normal life. Other people develop symptoms, which may progress and worsen as heart function worsens.
Symptoms of Dilated cardiomyopathy can occur at any age and may include:
• Heart failure symptoms (shortness of breath and fatigue).
• Swelling of the lower extremities.
• Fatigue (feeling overly tired).
• Weight gain.
• Fainting (caused by conditions such as irregular heart rhythms, abnormal responses of the blood vessels during exercise, or no cause may be found).
Diagnosis
Dilated cardiomyopathy is diagnosed based on medical history (your symptoms and family history), physical exam, blood tests, electrocardiogram (ECG or EKG), chest X-ray, echocardiogram, exercise stress test, cardiac catheterization, CT scan, and MRI. Another test rarely done to determine the cause of a cardiomyopathy is a myocardial biopsy, or heart biopsy, where a tissue sample is taken from the heart and examined under a microsope to determine the cause of the symptoms.
Treatment
Treatment of dilated cardiomyopathy is aimed at decreasing the heart size and the substances in the bloodstream that enlarge the heart and ultimately lead to worsened symptoms.
• Medications: To manage heart failure, most people improve by taking drugs, such as a beta-blocker, ACE inhibitor an ARB, and/or diuretics.
• Lifestyle changes: In case of heart failure, sodium should be restricted to 2,000-3,000 mg per day -for the rest of life. Doctor may recommend aerobic exercise, but heavy weight lifting is not allowed.
• People with severe Dilated cardiomyopathy may need one of the following surgeries: Cardiac resynchronization by biventricular pacemaker. For some people with Dilated cardiomyopathy, stimulating both the right and left ventricles with this pacemaker improves the heart's ability to contract with more force, thereby improving symptoms and increasing the length of time a person can exercise.
• Implantable cardioverter defibrillators (ICD). ICDs are suggested for people at risk for life-threatening arrhythmias or sudden cardiac death.
• Surgery. Conventional surgeries for coronary artery disease or valvular disease may be recommended. Some people may be eligible for surgical repair of the left ventricle or placement of a cardiac assist device.
Dilated Cardiomyopathy Emerging Drugs Chapters
This segment of the Dilated Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dilated Cardiomyopathy Emerging Drugs
• ARRY-371797: Pfizer
Pfizer is conducting a phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 in patients with symptomatic Dilated Cardiomyopathy due to a Lamin A/C gene mutation. This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a gene encoding the lamin A/C protein (LMNA) mutation. The study will further evaluate a dose level of ARRY-371797 that has shown preliminary efficacy and safety in this patient population. After the primary analysis has been performed, eligible patients may receive open-label treatment with ARRY-371797.
• Ifetroban: Cumberland Pharmaceuticals
Ifetroban is a selective and potent thromboxane-prostanoid receptor (TPr) antagonist. Preclinical work on this molecule demonstrated that blocking TPr with ifetroban improves cardiac survival while increasing cardiac output in multiple animal models. These encouraging findings compelled Cumberland to develop a clinical program to evaluate ifetroban for the treatment of DMD cardiomyopathy.
Ifetroban is a pharmacological antagonist of the thromboxane A2 / prostaglandin endoperoxide receptor (TPR). Ifetroban exhibits high-affinity for TPRs on platelets, vascular smooth muscle and certain other cell types and lacks agonistic activity. Ifetroban also displays anti-platelet and antivasospastic activities and is effective in certain preclinical models of vasospasm, thrombosis, reperfusion injury and endothelial dysfunction, including models that are insensitive to aspirin.
Further product details are provided in the report……..
Dilated Cardiomyopathy: Therapeutic Assessment
This segment of the report provides insights about the different Dilated Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Dilated Cardiomyopathy
There are approx. 5+ key companies which are developing the therapies for Dilated Cardiomyopathy. The companies which have their Dilated Cardiomyopathy drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Pfizer, Cumberland Pharmaceuticals, Berlin Cures etc.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Dilated Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular

• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Peptide aptamers
• Nucleotide aptamers

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dilated Cardiomyopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dilated Cardiomyopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dilated Cardiomyopathy drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Dilated Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Dilated Cardiomyopathy.
• In September 2020, MyoKardia doses first patient in phase 2 clinical trial of Danicamtiv in Genetic Dilated Cardiomyopathy. In clinical studies, danicamtiv has been well tolerated and has been shown to activate myosin, resulting in enhanced left ventricular contractility, including meaningful improvements in stroke volume, and improved left atrial volume and function.
Dilated Cardiomyopathy Report Insights
• Dilated Cardiomyopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Dilated Cardiomyopathy Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Dilated Cardiomyopathy drugs?
• How many Dilated Cardiomyopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dilated Cardiomyopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dilated Cardiomyopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dilated Cardiomyopathy and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Pfizer
• Berlin Cures
• Cumberland Pharmaceuticals
Key Products
• ARRY-371797
• Ifetroban
• BC 007